Flow cytometry-based quantification of tumor fibroblasts showed that artLCMV-TRP2 treatment precipitated a significant expansion of PDPN+ EYFP+ FSCs (Fig. 4d), while the proportion of EYFP+ PDPN+ FSCs in TDLNs remained unchanged (Supplementary Fig. 4f). This evidence concerns the gene PDPN and neoplasm.